At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GENB Generate Biomedicines
Pre-Mkt 08-21 09:13:56 EDT
15.99
-0.98
-5.77%
盘前16.21
+0.22+1.38%
09:07 EDT
High16.85Low15.74Vol952.70K
Open16.76D1 Closing16.97Amplitude6.51%
Mkt Cap2.05BTradable Cap964.01MTotal Shares128.19M
T/O15.40MT/O Rate1.58%Tradable Shares60.29M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)
TIPRANKS  ·  08-17
Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)
Generate Biomedicines Shares Fall Following Q2 Financial Results
MT Newswires Live  ·  08-07
Generate Biomedicines Shares Fall Following Q2 Financial Results
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Benzinga Earnings  ·  08-06
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Generate Biomedicines - Q2 Revenue $6.30 Mln
THOMSON REUTERS  ·  08-06
Generate Biomedicines - Q2 Revenue $6.30 Mln
Generate Biomedicines: Existing Cash, Cash Equivalents, and Marketable Securities Sufficient to Fund Current Operating Plan into H1 2028
THOMSON REUTERS  ·  08-06
Generate Biomedicines: Existing Cash, Cash Equivalents, and Marketable Securities Sufficient to Fund Current Operating Plan into H1 2028
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  08-06
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million
Reuters  ·  08-06
Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million
Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline
Reuters  ·  06-29
Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline
Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)
TIPRANKS  ·  06-25
Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)
Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)
TIPRANKS  ·  06-15
Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x
Simply Wall St.  ·  06-01
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x
Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference
Reuters  ·  05-29
Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference
Generate Biomedicines publishes corporate presentation on programmable biology drug design platform
Reuters  ·  05-27
Generate Biomedicines publishes corporate presentation on programmable biology drug design platform
Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment
Stock Track  ·  05-22
Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment
Simply Wall St.  ·  05-22
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment
U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags
Dow Jones  ·  05-19
U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags
Generate Biomedicines Is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  05-15
Generate Biomedicines Is Maintained at Overweight by Morgan Stanley
Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley
TIPRANKS  ·  05-14
Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley
Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating
MT Newswires Live  ·  05-14
Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating
Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)
TIPRANKS  ·  05-08
Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)

Introduction

Company Name.
Generate Biomedicines
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Generate Biomedicines, Inc. was incorporated in August 2018 under Delaware law. As a clinical-stage generative biology company, it pioneered an AI-driven biotechnology platform called the Generate Platform, which combines computational models with scalable biological hardware to design and develop novel therapeutic proteins. Its most advanced candidate, GB-0895, is a computationally engineered anti-TSLP monoclonal antibody currently in a pivotal Phase 3 trial for severe asthma. The platform's capabilities have been further demonstrated by advancing two additional oncology candidates into Phase 1 trials by 2026.
Issue price:
--